OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
Clinical trials for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) explained in plain language.
Never miss a new study
Get alerted when new OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) trials appear
Sign up with your email to follow new studies for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a common supplement help hearts pump better?
Disease control Recruiting nowThis study tests a medicine called ademetionine in 44 adults with a heart condition that blocks blood flow. Participants will take either the medicine or a placebo for 16 weeks. Researchers will check if it helps with exercise, symptoms, and heart function.
Matched conditions: OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
Phase: PHASE2 • Sponsor: China National Center for Cardiovascular Diseases • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Heart drug mavacamten under real-world safety watch in japan
Disease control Recruiting nowThis study monitors the real-world safety and effectiveness of mavacamten in about 200 people in Japan who have obstructive hypertrophic cardiomyopathy, a condition where the heart muscle thickens and blocks blood flow. Participants will be followed to track any side effects and …
Matched conditions: OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Heart drug mavacamten under the microscope: Real-World study launches
Knowledge-focused Recruiting nowThis study is following about 362 adults with a type of heart disease called obstructive hypertrophic cardiomyopathy who are taking the drug mavacamten. Researchers want to see how the drug works in real doctor's offices, not just in strict research settings. They will track thin…
Matched conditions: OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC